Archemix Signs MicroRNA Deal
Luke Timmerman7/23/09
Cambridge, MA-based Archemix, the developer of a new class of drug called aptamers, said today it has formed an R&D collaboration with Boulder, CO-based miRagen Therapeutics, a developer of microRNA treatments. The two companies will plan to attach aptamer drugs to microRNA molecules with a goal of delivering the compounds inside cells. Both companies will contribute resources to the collaboration, and miRagen is getting options to do exclusive development of drugs that emerge from the partnership, although detailed financial terms weren’t disclosed.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
